The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Two endocrinologists who live with type 1 diabetes debate this issue at the Advanced Technologies & Treatments for Diabetes ...

Mizuho initiated coverage of Senseonics (SENS) with an Outperform rating and $2 price target citing positive survey data for continued ...

Researchers show that using continuous glucose monitors can help measure glucose accurately during DKA and potentially prevent ICUs from being overwhelmed. Diabetic ketoacidosis is a common severe ...

1 Continuous glucose monitors (CGMs) are revealing surprising metabolic insights, and now, non-diabetics are using them to optimize their health like never before. Image Credit: Halfpoint ...

Among patients with type-2 diabetes (T2D) requiring insulin therapy, automated insulin delivery (AID) resulted in a greater ...

(HealthDay News) — Continuous glucose monitoring (CGM) can overestimate glycemic responses, according to a study published online in The American Journal of Clinical Nutrition. Katie M.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

In a world where diabetes management is evolving at a rapid pace, the spotlight shines on non-invasive glucose monitors that ...

Shares traded 8.5% higher at $72.55. The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 ...

In a study, published in CHEST Critical Care, University of Michigan researchers show that using continuous glucose monitors can help measure glucose accurately during DKA and potentially prevent ...